Revenue segments as reported by the company.

MedSurg and Neurotechnology

Orthopaedics and Spine

Orthopaedics

MedSurg

Neurotechnology and Spine

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research, development and engineering

Selling, general and administrative

Recall charges

Amortization of intangible assets

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Stryker

MAKO was a publicly traded medical device company based in Florida. On September 25, 2013, the Board of Directors of Mako Surgical accepted a deal to be acquired by Stryker for $1.65B. The deal closed in December 2013. The company manufactures and markets surgical robotic arm assistance platforms, most notably the RIO as well as orthopedic implants used by orthopedic surgeons for use in partial knee and total hip arthroplasty. They are known for their intellectual property of devices and have over 300 U.S. and foreign patents and patent applications.

MAKO Surgical Corp

Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Portage, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stryker (SYK) exceeds Q4 expectations, poised for growth in 2023

Stryker (SYK) delivered exceptional financial results in Q4 2022, surpassing expectations and demonstrating resilience amid challenges. The company is well-positioned for growth with a strong pipeline of products and a focus on margin expansion. Despite ongoing market complexities, Stryker remains optimistic about its future performance.

Stryker reports robust Q1 results and optimistic outlook for 2023

Stryker's strong Q1 performance driven by organic sales growth and increased EPS, with positive outlook for the full year.
Company recognized for workplace excellence, leading in robotics, and expecting growth in medical division.
Challenges include supply chain uncertainties, margin impacts, and market disruptions, but opportunities lie in stakeholder engagement and business expansion.
Overall, Stryker remains focused on innovation, debt reduction, and strategic acquisitions for future growth.

Stryker reports stellar Q2 results, eyes international growth opportunities

Stryker's Q2 performance reflects robust sales growth, margin improvement, and strategic acquisitions driving financial strength.
While facing challenges in the U.S. market and competitive landscapes, Stryker's focus on innovation and international growth presents promising opportunities.
The company's financial resilience, debt reduction strategy, and upcoming product launches position Stryker for sustained success and market expansion.
Overall, Stryker's strong performance, coupled with a focus on innovation and strategic growth initiatives, sets a positive trajectory for future success.

Stryker reports robust Q3 earnings, eyes international growth and M&A

Stryker's Q3 performance reflects strong sales growth and earnings increase, driven by key segments and product lines. Challenges include market competition and potential shifts in procedure trends, while opportunities exist in international expansion and strategic acquisitions.

Stryker exceeds $20B in sales, eyes continued growth and innovation

Stryker's Q4 performance showcased strong sales growth, margin expansion, and successful acquisitions, positioning the company for continued success.
While facing challenges in pricing and potential regulatory impacts, Stryker's focus on innovation and strategic growth initiatives presents promising opportunities.
The company's robust pipeline of innovative products and successful integration efforts highlight its resilience and potential for sustained growth.
With a solid financial foundation and strategic vision, Stryker is well-positioned to capitalize on market opportunities and drive future profitability.

Stryker reports strong Q1 growth, eyes international expansion opportunities

Stryker's Q1 2024 earnings call reflects strong performance, with double-digit organic sales growth and increased guidance for the full year.
The company's focus on innovation, successful acquisitions, and market recognition position it well for future growth and leadership in key segments.
While facing challenges like regulatory delays and market dependencies, Stryker remains optimistic about meeting targets and driving growth through new products and acquisitions.
Opportunities in international expansion, AI solutions, and continued market growth present avenues for sustained success and market leadership for Stryker.

Stryker reports robust Q2 earnings, raises 2024 outlook on acquisitions and margin expansion

Stryker's strong Q2 performance, strategic acquisitions, and focus on margin expansion position the company for continued growth. Despite challenges like foreign exchange rates and market softness in certain segments, Stryker's product strength, innovation pipeline, and international growth opportunities offer a positive outlook. With a commitment to driving margins and expanding its product portfolio, Stryker remains poised for sustained success in the medical technology industry.

Stryker reports robust Q3 performance with strong growth and strategic acquisitions

Stryker's Q3 showcased strong organic sales and EPS growth, driven by MedSurg and Neurotechnology segments.
Strategic acquisitions, record Mako installations, and operational efficiency improvements underpin performance.
Challenges in the ischemic stroke segment and competitor actions pose risks, while pricing trends and margin efficiencies are under scrutiny.
Opportunities lie in M&A expansion, growth in high-demand areas, and sustained market momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kalamazoo, Michigan, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will host a conference call on Thursday, January 27, 2022 at 4:30 p.m., Eastern Time, to discuss the Company's operating results for the quarter ended December 31, 2021 and provide an operational update. Final operating results for the quarter ended December 31, 2021 will be released at 4:05 p.m. that day.

Stryker to host conference call on January 27, 2022

Air Products and Chemicals

Bristol-Myers

Cardinal Health

Comcast

Cisco Systems

Illinois Tool Works

JPMorgan Chase & Co

Mastercard

Main Street Capital

Realty Income Corp

Sysco

AT&T

Verizon

We provide a summary of upcoming ex-dividend dates in a quick reference table.

Upcoming Ex-Dividend Dates: December 30-January 7, 2022

Shares of Microbot Medical Inc. MBOT, +7.11% rocketed 67.3% toward a nine-month high on heavy volume in premarket trading Monday, after the pre-clinical medical device company announced an agreement with Stryker Corp. SYK, +1.59% to develop the first dedicated robotic procedural kits for use in certain neurovascular procedures. Trading volume ballooned to 9.6 million shares, compared with the full-day average of about 49,000 shares.

Microbot's stock rockets on heavy volume after collaboration pact with Stryker on robotic procedural kits

Andersons

Alexandria Real Estate Equities

Balchem

Franklin Resources

CubeSmart

EastGroup Properties

Ensign Group

Four Corners Property Trust

Hingham Institution for Savings

Kennedy-Wilson Holdings

Lincoln Electric Hlds

MGM Growth Properties

National HealthCare

Nucor

TFI International

Toro

Washington Trust Bancorp

W. P. Carey

York Water

All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 9.0% and a median increase of 5.4%. I've tracked 524 increases in 2021.

20 Dividend Increases To Finish 2021

Broadcom

Bank of Nova Scotia

CME Group

Medtronic

McCormick

Altria

Philip Morris

SPDR S&P 500 ETF Trust

Xcel Energy

We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics as well as the next payout and pay date.

Upcoming Ex-Dividend Dates: December 21-January 3, 2021

AbbVie

Abbott Labs

C.H. Robinson Worldwide

Edison

Enbridge

Erie Indemnity

Hooker Furniture

Mid-America Apartment Communities

Pfizer

Hanover Insurance Group

Trinity Industries

Union Pacific

Zoetis

In this article series, we provide a weekly summary of dividend changes. A summary table provides relevant data and key statistics of dividend increases.

Dividend Increases: December 4-10, 2021

The shares of Stryker Corporation (NYSE: SYK) have received a $305 price target from Loop Capital. These are the details.

Stryker Stock (SYK): $305 Price Target From Loop Capital

CVS Health

The healthcare sector is often one of the most recession-resistant areas of the market given that its products and services remain in demand even as the economy enters a downturn. People value their health as this impacts their quality of life, allowing companies in the healthcare sector to see rather consistent results throughout the economic cycle.

2 Healthcare Stocks Delivering Double-Digit Dividend Increases

Stryker Corp. SYK, +0.28% said Thursday it will raise its quarterly dividend by 10.3%, to 69.5 cents a share from 63 cents. The medical technology company's new dividend will be payable Jan. 31 to shareholders of record on Dec. 31.

Stryker raises dividend by 10%, to lift implied yield above 1%

ATLANTA, Dec. 9, 2021 /PRNewswire/ -- Atlanta- and New York-based Moss & Gilmore LLP announced today the settlement with the U.S. Department of Justice ("DOJ") and State of Georgia of a False Claims Act ("FCA") lawsuit against Defendants Jeffrey M. Gallups, M.D.

ENT Practice Milton Hall Surgical Associates, LLC, Jeffrey M. Gallups, M.D.

Fortune Brands Home & Security

After years of a low interest rate environment, many investors have turned to equities not only for the growth potential but also for solid and dependable dividends, which help to provide an income stream.

5 ‘Strong Buy' Blue Chip Stocks With Dividend Hikes Expected This Week

Eastman Chemical

Merck

5 Buy-Rated Blue Chip Stocks With Dividends Expected to Rise This Week

Stryker is one of the largest medical device companies in the world, yet it appears to have plenty of growth left in the tank.

Is This Powerhouse Medical Devices Stock a Buy?

AdaptHealth Corp

AHCO vs. SYK: Which Stock Is the Better Value Option?

AHCO vs. SYK: Which Stock Should Value Investors Buy Now?

MAHWAH, N.J.--(BUSINESS WIRE)--Stryker launched the Prophecy Infinity Resect-Through Guides for use in total ankle replacement surgeries.

Stryker Launches New Prophecy Infinity Resect-Through Guides

SYK's investment-grade credit rating mirrors its cash generative ability, successful M&A expansion strategy, and leading industry position. Q3 results came below expectations because of challenging trends related to Chinese pricing regulations, combined with COVID-variants disruptions.

Stryker: A Q3 Earnings Hiccup In A Broader Bullish Trend

Despite pandemic-led disruptions, Stryker's (SYK) third-quarter earnings reflect strong performance across Orthopaedics, MedSurg and Neurotechnology and Spine segments.

Stryker (SYK) Earnings and Revenues Miss Estimates in Q3

News for Stryker Stock (SYK)